Clik here to view.
ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to...
DUBLIN ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the signing of a...
View ArticleClik here to view.
Clik here to view.
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific
SEOUL, South Korea Kap-Seok Yang, CEO of Macrogen (KOSDAQ: 038290), announced on January 13 that the company has signed a strategic License and Supply Agreement with Thermo Fisher Scientific. The...
View ArticleClik here to view.
Allele and Astellas Enter into an Expanded License for the Development of...
SAN DIEGO Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., “Allele”), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO:...
View ArticleClik here to view.
PPD拓展中国临床开发和实验室能力
北卡罗莱纳州威尔明顿 (美国商业资讯)–PPD, Inc. (PPD)已拓展其中国业务和领导团队，以便为国际和中国生物制药公司提供更完善的临床开发、实验室、监管、研究单位实施、患者募集和审批后服务。 PPD的拓展包括扩大其位于北京和上海的临床开发办事处，并在广州和沈阳开设新的办事处。2020年，PPD®...
View ArticleClik here to view.
武田薬品：事業変革の進捗と優先事項の概要について第38回J.P. モルガン・ヘルスケア・カンファレンスにて発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 当社は、このたび、第38回J.P....
View ArticleClik here to view.
Takeda to Outline Progress on Business Transformation and Priorities at the...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will provide an update on the progress of its business transformation and priorities today...
View ArticleClik here to view.
GeneMedicine Appoints MIT Professor Robert S. Langer, Sc.D to Its Scientific...
SEOUL, South Korea GeneMedicine Co., Ltd., a leader in the field of oncolytic adenovirus platform for the treatment of intractable cancers, announced today that the company has appointed Robert S....
View ArticleClik here to view.
Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
Lucence Presents Data Demonstrating Potential of AmpliMARK™-Powered...
MIAMI Singapore-based precision oncology startup Lucence, on the heels of its series A funding, is sharing early data highlighting the capabilities of its liquid biopsy technology to detect somatic...
View ArticleClik here to view.
武田将在第38届年度J.P.摩根健康产业大会上介绍业务转型和优先工作的进展情况
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（以下称“武田”）将于今日在第38届年度J.P.摩根健康产业大会(J.P. Morgan Healthcare...
View ArticleClik here to view.
Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions...
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies...
TORONTO & SINGAPORE AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biotechnology company committed to speedily developing affordable cancer therapies, and Cyclica, a...
View ArticleClik here to view.
INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec...
SEONGNAM, South Korea Insert new paragraph after the 1st paragraph under the “ADDITIONAL INFORMATION AND WHERE TO FIND IT“ section of the release. The corrected release reads: ALPHA HOLDINGS SENDS...
View ArticleClik here to view.
Clik here to view.
‘First Mover to Game Changer’: Celltrion announces 2020-2030 strategy at the...
SAN FRANCISCO Celltrion today announced the company’s vision for the next decade at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA. Celltrion’s Chairman Jung Jin Seo...
View ArticleClik here to view.
武田薬品：事業変革の進捗と優先事項の概要について第38回J.P. モルガン・ヘルスケア・カンファレンスにて発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 当社は、このたび、第38回J.P....
View ArticleClik here to view.
Takeda to Outline Progress on Business Transformation and Priorities at the...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will provide an update on the progress of its business transformation and priorities today...
View ArticleClik here to view.
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars...
SINGAPORE Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung...
View ArticleClik here to view.
MEVION S250i Selected by Jinshazhou Hospital to Equip New Proton Therapy...
LITTLETON, Mass. Mevion Medical Systems is pleased to announce it has signed an agreement for the sale of a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning to Jinshazhou...
View Article